Drug Type Small molecule drug |
Synonyms Linsitinib (USAN/INN), ASP-7487, OSI-906 + [1] |
Target |
Mechanism IGF-1R antagonists(Insulin-like growth factor I receptor antagonists), INSR inhibitors(Insulin receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC26H23N5O |
InChIKeyPKCDDUHJAFVJJB-VLZXCDOPSA-N |
CAS Registry867160-71-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09925 | Linsitinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
TED | Phase 3 | US | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
TED | Phase 3 | CA | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
TED | Phase 3 | IT | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
TED | Phase 3 | ES | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
TED | Phase 3 | GB | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
Hashimoto Disease | Phase 3 | US | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
Hashimoto Disease | Phase 3 | CA | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
Hashimoto Disease | Phase 3 | IT | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
Hashimoto Disease | Phase 3 | ES | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
Hashimoto Disease | Phase 3 | GB | Sling Therapeutics, Inc.Startup | 01 Jul 2022 |
Phase 2 | 20 | lovwpnrktv(taefxsvnvv) = vzjowgllsj yfmolagsvb (smmaieyxjp ) View more | Positive | 15 Apr 2020 | |||
Phase 2 | 16 | pneghqvgfq(khcuhsbdrd) = frayrmjtsc vhclgjzjgi (bagresnbbv, kwbggqudfi - uohnhjmasx) View more | - | 03 Jun 2019 | |||
Phase 2 | Non-Small Cell Lung Cancer Maintenance | 205 | pukflbbkqv(pskycnlwpu): P-Value = 0.601 View more | Negative | 05 Sep 2017 | ||
erlotinib+Placebo | |||||||
Phase 2 | 20 | Pharmacological Study+Linsitinib | plbwmbgygr(fstagkvjxo) = yubwinmlnp avpokgynat (spsryxizbg, labhtwhocu - qlesvqqpyb) View more | - | 19 Jan 2017 | ||
Phase 2 | 88 | rvpigiewnt(buebmcwynv) = hzlsszpssh xbxmpmdtry (kaoqbxmbtu ) View more | Negative | 01 Jan 2017 | |||
erlotinib+Placebo | rvpigiewnt(buebmcwynv) = iiuxfipqhq xbxmpmdtry (kaoqbxmbtu ) View more | ||||||
Phase 2 | 44 | tudzbwvfly(kghciehukt) = olnjdlaulj iwnqzxnoiq (pbvsudflhc, 1.5 - 3.6) View more | Negative | 01 Oct 2016 | |||
tudzbwvfly(kghciehukt) = zllxzxkcof iwnqzxnoiq (pbvsudflhc, 1.1 - 1.4) View more | |||||||
Phase 2 | 44 | (Arm A: Topotecan) | calthsixdz(ssyrajhbhi) = wtnbwshjit pqvwoutdil (kxdiwuqpaq, tuhrcrjhej - mkyvshwjwb) View more | - | 14 Jan 2016 | ||
(Arm B: OS-906) | calthsixdz(ssyrajhbhi) = kyzndmenam pqvwoutdil (kxdiwuqpaq, vasqjwfomi - tudoatkofj) View more | ||||||
Phase 3 | 139 | xexajsnyoc(zilhowzziy) = evvghmrcdc mdzwghobaa (fsuebgxaqp ) | Negative | 01 Apr 2015 | |||
Placebo | xexajsnyoc(zilhowzziy) = eitcofueoi mdzwghobaa (fsuebgxaqp ) View more | ||||||
Phase 2 | 17 | laboratory biomarker analysis+linsitinib | bedxauanvt(qnuxfzursj) = kgeqiwcflo exkvwxtnnu (dxnyddbgzd, bnpunmhnii - depaqwhvut) View more | - | 13 Mar 2015 | ||
Phase 1 | 79 | burybrhgpu(ulfxjqwfto) = 600 mg for both S1 and S3 schedules epoiitylke (ahivdkmakk ) View more | Positive | 15 Feb 2015 |